Published by Josh White on 27th August 2025
(Sharecast News) - Faron Pharmaceuticals reported a series of first-half clinical and financial milestones on Wednesday, as it advanced its lead asset, bexmarilimab, through late-stage development in high-risk myelodysplastic syndromes (HR-MDS).
URL: http://www.digitallook.com/dl/news/story/35312311/...